Brain alterations and clinical symptoms of dementia in diabetes: Aβ/tau-dependent and independent mechanisms

Frontiers in Endocrinology

Volumn 5, Issue SEP, 2014, Pages

  Sato, Naoyuki ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Abeta; Alzheimer disease; Dementia; Diabetes mellitus; Tauopathies

Indexed keywords

HEMOGLOBIN A1C; TAU PROTEIN;

ALZHEIMER DISEASE; COGNITION; DEMENTIA; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; MITOCHONDRIAL RESPIRATION; NONHUMAN; REVIEW;

EID: 84987816344     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00143     Document Type: Review

References (136)

1. Dartigues JF. Alzheimer's disease: a global challenge for the 21st century. Lancet Neurol (2009) 8(12):1082-3. doi: 10.1016/S1474-4422(09)70298-4
2. Type 2 diabetes epidemic: a global education. Lancet (2009) 374(9702):1654. doi:10.1016/S0140-6736(09)61974-7
3. Roberts RO, Knopman DS, Przybelski SA, Mielke MM, Kantarci K, Preboske GM, et al. Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology (2014) 82(13):1132-41. doi:10.1212/WNL.0000000000000269
4. Morris JK, Vidoni ED, Honea RA, Burns JM. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging (2014) 35(3):585-9. doi:10.1016/j.neurobiolaging.2013.09.033
5. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother (2009) 9(5):617-30. doi:10.1586/ern.09.18
6. Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis (2009) 16(4):677-85. doi:10.3233/JAD-2009-1011
7. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology (1999) 53(9):1937-42. doi:10.1212/WNL.53.9.1937
8. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology (2010) 75(9):764-70. doi:10.1212/WNL.0b013e3181eee25f
9. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol (2009) 5(12):649-58. doi:10.1038/nrneurol.2009.175
10. Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short-and long-term modification by non-genetic risk factors. Front Aging Neurosci (2013) 5:64. doi:10.3389/fnagi.2013.00064
11. Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care (2013) 36(12):4036-42. doi:10.2337/dc13-0143
12. Garcia-Casares N, Berthier ML, Jorge RE, Gonzalez-Alegre P, Gutiérrez Cardo A, Rioja Villodres J, et al. Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. J Alzheimers Dis (2014) 40(2):375-86. doi:10.3233/JAD-131736
13. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 82(4):239-59. doi:10.1007/BF00308809
14. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 23(3):994-1005.
15. Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, da Silva CG, Guimarães DM, Szczupak D, et al. Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles. Brain (2013) 136(Pt 12):3738-52. doi:10.1093/brain/awt273
16. Mann DM. The topographic distribution of brain atrophy in Alzheimer's disease. Acta Neuropathol (1991) 83(1):81-6. doi:10.1007/BF00294434
17. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 25(34):7709-17. doi:10.1523/JNEUROSCI.2177-05.2005
18. Sorg C, Riedl V, Mühlau M, Calhoun VD, Eichele T, Läer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 104(47):18760-5. doi:10.1073/pnas.0708803104
19. Chen YC, Jiao Y, Cui Y, Shang SA, Ding J, Feng Y, et al. Aberrant brain functional connectivity related to insulin resistance in type 2 diabetes: a resting-state FMRI study. Diabetes Care (2014) 37(6):1689-96. doi:10.2337/dc13-2127
20. Hoogenboom WS, Marder TJ, Flores VL, Huisman S, Eaton HP, Schneiderman JS, et al. Cerebral white matter integrity and resting-state functional connectivity in middle-aged patients with type 2 diabetes. Diabetes (2014) 63(2):728-38. doi:10.2337/db13-1219
21. Cui Y, Jiao Y, Chen YC, Wang K, Gao B, Wen S, et al. Altered spontaneous brain activity in type 2 diabetes: a resting-state functional MRI study. Diabetes (2014) 63(2):749-60. doi:10.2337/db13-0519
22. Marder TJ, Flores VL, Bolo NR, Hoogenboom WS, Simonson DC, Jacobson AM, et al. Task-induced brain activity patterns in type 2 diabetes: a potential biomarker for cognitive decline. Diabetes (2014). doi:10.2337/db13-1783
23. Wang Z, Yan C, Zhao C, Qi Z, Zhou W, Lu J, et al. Spatial patterns of intrinsic brain activity in mild cognitive impairment and Alzheimer's disease: a resting-state functional MRI study. Hum Brain Mapp (2011) 32(10):1720-40. doi:10.1002/hbm.21140
24. Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 74(1):44-50. doi:10.1136/jnnp.74.1.44
25. Perlmuter LC, Hakami MK, Hodgson-Harrington C, Ginsberg J, Katz J, Singer DE, et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med (1984) 77(6):1043-8. doi:10.1016/0002-9343(84)90186-4
26. Goh DA, Dong Y, Lee WY, Koay WI, Tay SZ, Soon D, et al. A pilot study to examine the correlation between cognition and blood biomarkers in a Singapore Chinese male cohort with type 2 diabetes mellitus. PLoS One (2014) 9(5):e96874. doi:10.1371/journal.pone.0096874
27. Holmes CS, Hayford JT, Gonzalez JL, Weydert JA. A survey of cognitive functioning at difference glucose levels in diabetic persons. Diabetes Care (1983) 6(2):180-5. doi:10.2337/diacare.6.2.180
28. Nazaribadie M, Amini M, Ahmadpanah M, Asgari K, Jamlipaghale S, Nazaribadie S. Executive functions and information processing in patients with type 2 diabetes in comparison to pre-diabetic patients. J Diabetes Metab Disord (2014) 13(1):27. doi:10.1186/2251-6581-13-27
29. Watari K, Letamendi A, Elderkin-Thompson V, Haroon E, Miller J, Darwin C, et al. Cognitive function in adults with type 2 diabetes and major depression. Arch Clin Neuropsychol (2006) 21(8):787-96. doi:10.1016/j.acn.2006.06.014
30. Sakurai T, Kawashima S, Satake S, Miura H, Tokuda H, Toba K. Differential subtypes of diabetic older adults diagnosed with Alzheimer's disease. Geriatr Gerontol Int (2014) 14(Suppl 2):62-70. doi:10.1111/ggi.12250
31. Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology (2014) 83(5):434-40. doi:10.1212/WNL.0000000000000650
32. Reid W, Broe G, Creasey H, Grayson D, McCusker E, Bennett H, et al. Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease. A study of a community-based population. Arch Neurol (1996) 53(10):1056-61. doi:10.1001/archneur.1996.00550100142023
33. Huber SJ, Shuttleworth EC, Freidenberg DL. Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Arch Neurol (1989) 46(12):1287-91. doi:10.1001/archneur.1989.00520480029015
34. Starkstein SE, Sabe L, Vazquez S, Teson A, Petracca G, Chemerinski E, et al. Neuropsychological, psychiatric, and cerebral blood flow findings in vascular dementia and Alzheimer's disease. Stroke (1996) 27(3):408-14. doi:10.1161/01.STR.27.3.408
35. Haxby JV, Grady CL, Koss E, Horwitz B, Schapiro M, Friedland RP, et al. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology (1988) 38(12):1853-63. doi:10.1212/WNL.38.12.1853
36. Fukui T, Lee E, Kitamura M, Hosoda H, Bokui C, Ikusu K, et al. Visuospatial dysfunction may be a key in the differentiation between Alzheimer's disease and subcortical cognitive impairment in moderate to severe stages. Dement Geriatr Cogn Disord (2009) 28(4):288-94. doi:10.1159/000245157
37. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain (1988) 111(Pt 3):695-718. doi:10.1093/brain/111.3.695
38. Mori T, Shimada H, Shinotoh H, Hirano S, Eguchi Y, Yamada M, et al. Apathy correlates with prefrontal amyloid beta deposition in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2014) 85(4):449-55. doi:10.1136/jnnp-2013-306110
39. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: disorders of behaviour. Br J Psychiatry (1990) 157:86-94. doi:10.1192/bjp.157.1.86
40. Rothman SM, Mattson MP. Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromolecular Med (2012) 14(3):194-204. doi:10.1007/s12017-012-8181-2
41. Patterson MB, Mack JL, Neundorfer MM, Martin RJ, Smyth KA, Whitehouse PJ. Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the Cleveland scale for activities of daily living. Alzheimer Dis Assoc Disord (1992) 6(3):145-63. doi:10.1097/00002093-199206030-00003
42. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke (2009) 40(3 Suppl):S40-4. doi:10.1161/STROKEAHA.108.533638
43. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 77(1):82-102. doi:10.1002/msj.20155
44. Neltner JH, Abner EL, Baker S, Schmitt FA, Kryscio RJ, Jicha GA, et al. Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2014) 137(Pt 1):255-67. doi:10.1093/brain/awt318
45. Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients? J Alzheimers Dis (2012) 32(3):765-72. doi:10.3233/JAD-2012-121012
46. Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, et al. Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's disease neuroimaging initiative controls. Neurobiol Aging (2013) 34(8):1996-2002. doi:10.1016/j.neurobiolaging.2013.02.003
47. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes (1999) 48(9):1856-62. doi:10.2337/diabetes.48.9.1856
48. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab (2006) 32(5 Pt 1):403-14. doi:10.1016/S1262-3636(07)70298-7
49. Muris DM, Houben AJ, Schram MT, Stehouwer CD. Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol (2012) 32(12):3082-94. doi:10.1161/ATVBAHA.112.300291
50. van Elderen SG, de Roos A, de Craen AJ, Westendorp RG, Blauw GJ, Jukema JW, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology (2010) 75(11):997-1002. doi:10.1212/WNL.0b013e3181f25f06
51. Bruce DG, Davis WA, Starkstein SE, Davis TM. Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: the Fremantle diabetes study. J Alzheimers Dis (2014).
52. Cheung CY, Ong YT, Ikram MK, Ong SY, Li X, Hilal S, et al. Microvascular network alterations in the retina of patients with Alzheimer's disease. Alzheimers Dement (2014) 10(2):135-42. doi:10.1016/j.jalz.2013.06.009
53. Cerani A, Tetreault N, Menard C, Lapalme E, Patel C, Sitaras N, et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab (2013) 18(4):505-18. doi:10.1016/j.cmet.2013.09.003
54. West RK, Ravona-Springer R, Schmeidler J, Leroith D, Koifman K, Guerrero-Berroa E, et al. The Association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control. Am J Geriatr Psychiatry (2014). doi:10.1016/j.jagp.2014.01.010
55. Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, et al. F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging (2014) 35(9):2096-106. doi:10.1016/j.neurobiolaging.2014.03.006
56. Ossenkoppele R, van der Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology (2014) 82(20):1768-75. doi:10.1212/WNL.0000000000000432
57. Pilotto A, Noale M, Maggi S, Addante F, Tiengo A, Perin PC, et al. Hypoglycemia is independently associated with multidimensional impairment in elderly diabetic patients. Biomed Res Int (2014) 2014:906103. doi:10.1155/2014/906103
58. Rasmussen P, Wyss MT, Lundby C. Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans. FASEB J (2011) 25(9):2865-73. doi:10.1096/fj.11-183822
59. Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B. In vivo evidence for lactate as a neuronal energy source. J Neurosci (2011) 31(20):7477-85. doi:10.1523/JNEUROSCI.0415-11.2011
60. Sherin A, Anu J, Peeyush KT, Smijin S, Anitha M, Roshni BT, et al. Cholinergic and GABAergic receptor functional deficit in the hippocampus of insulin-induced hypoglycemic and streptozotocin-induced diabetic rats. Neuroscience (2012) 202:69-76. doi:10.1016/j.neuroscience.2011.11.058
61. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA (2009) 301(15):1565-72. doi:10.1001/jama.2009.460
62. Roberts RO, Knopman DS, Cha RH, Mielke MM, Pankratz VS, Boeve BF, et al. Diabetes and elevated hemoglobin a1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med (2014) 55(5):759-64. doi:10.2967/jnumed.113.132647
63. Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Floel A. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology (2013) 81(20):1746-52. doi:10.1212/01.wnl.0000435561.00234.ee
64. Thiebaud N, Johnson MC, Butler JL, Bell GA, Ferguson KL, Fadool AR, et al. Hyperlipidemic diet causes loss of olfactory sensory neurons, reduces olfactory discrimination, and disrupts odor-reversal learning. J Neurosci (2014) 34(20):6970-84. doi:10.1523/JNEUROSCI.3366-13.2014
65. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 10(11):969-77. doi:10.1016/S1474-4422(11)70188-0
66. Strachan MW, Price JF. Diabetes. Cognitive decline and T2DM-a disconnect in the evidence? Nat Rev Endocrinol (2014) 10(5):258-60. doi:10.1038/nrendo.2014.38
67. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature (1978) 272(5656):827-9. doi:10.1038/272827a0
68. Wickelgren I. Tracking insulin to the mind. Science (1998) 280(5363):517-9. doi:10.1126/science.280.5363.517
69. Hill JM, Lesniak MA, Pert CB, Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience (1986) 17(4):1127-38. doi:10.1016/0306-4522(86)90082-5
70. Banks WA. The source of cerebral insulin. Eur J Pharmacol (2004) 490(1-3):5-12. doi:10.1016/j.ejphar.2004.02.040
71. Molnár G, Faragó N, Kocsis ÁK, Rózsa M, Lovas S, Boldog E, et al. GABAergic neurogliaform cells represent local sources of insulin in the cerebral cortex. J Neurosci (2014) 34(4):1133-7. doi:10.1523/JNEUROSCI.4082-13.2014
72. Shemer J, Raizada MK, Masters BA, Ota A, LeRoith D. Insulin-like growth factor I receptors in neuronal and glial cells. Characterization and biological effects in primary culture. J Biol Chem (1987) 262(16):7693-9.
73. Araujo DM, Lapchak PA, Collier B, Chabot JG, Quirion R. Insulin-like growth factor-1 (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. Brain Res (1989) 484(1-2):130-8.
74. Rotwein P, Burgess SK, Milbrandt JD, Krause JE. Differential expression of insulin-like growth factor genes in rat central nervous system. Proc Natl Acad Sci U S A (1988) 85(1):265-9. doi:10.1073/pnas.85.1.265
75. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, et al. A critical role for IGF-II in memory consolidation and enhancement. Nature (2011) 469(7331):491-7. doi:10.1038/nature09667
76. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature (1991) 352(6330):73-7. doi:10.1038/352073a0
77. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J (1993) 296(Pt 1):15-9.
78. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995) 378(6559):785-9. doi:10.1038/378785a0
79. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res (2008) 5(5):438-47. doi:10.2174/156720508785908919
80. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 101(9):3100-5. doi:10.1073/pnas.0308724101
81. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol (2011) 225(1):54-62. doi:10.1002/path.2912
82. Steculorum SM, Solas M, Bruning JC. The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimers Dement (2014) 10(1 Suppl):S3-11. doi:10.1016/j.jalz.2013.12.008
83. Diegues JC, Pauli JR, Luciano E, de AlmeidaLeme JA, de Moura LP, Dalia RA, et al. Spatial memory in sedentary and trained diabetic rats: molecular mechanisms. Hippocampus (2014) 24(6):703-11. doi:10.1002/hipo.22261
84. Edwards JL, Quattrini A, Lentz SI, Figueroa-Romero C, Cerri F, Backus C, et al. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia (2010) 53(1):160-9. doi:10.1007/s00125-009-1553-y
85. Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology (2012) 153(1):329-38. doi:10.1210/en.2011-1502
86. Chowdhury SK, Smith DR, Fernyhough P. The role of aberrant mitochondrial bioenergetics in diabetic neuropathy. Neurobiol Dis (2013) 51:56-65. doi:10.1016/j.nbd.2012.03.016
87. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2013) 36(10):2981-7. doi:10.2337/dc13-0229
88. Goodarzi MO. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2014) 37(6):e150. doi:10.2337/dc13-2473
89. Saleh A, Chowdhury SK, Smith DR, Balakrishnan S, Tessler L, Schartner E, et al. Diabetes impairs an interleukin-1beta-dependent pathway that enhances neurite outgrowth through JAK/STAT3 modulation of mitochondrial bioenergetics in adult sensory neurons. Mol Brain (2013) 6:45. doi:10.1186/1756-6606-6-45
90. Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol (2006) 2(11):620-8. doi:10.1038/ncpneuro0320
91. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349(6311):704-6. doi:10.1038/349704a0
92. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375(6534):754-60. doi:10.1038/375754a0
93. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 32(18):4693-7. doi:10.1021/bi00069a001
94. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 13(1):45-53. doi:10.1016/0896-6273(94)90458-8
95. Kalaria RN. Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol (2009) 5(6):305-6. doi:10.1038/nrneurol.2009.72
96. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol (1994) 126(1):88-94. doi:10.1006/exnr.1994.1044
97. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis (2000) 7(4):321-31. doi:10.1006/nbdi.2000.0366
98. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J (2004) 18(7):902-4. doi:10.1096/fj.03-0978fje
99. Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, et al. Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy (2012) 8:12. doi:10.4161/auto.21861
100. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging (2012) 33(1):.e113-27. doi:10.1016/j.neurobiolaging.2010.05.026
101. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A (2010) 107(15):7036-41. doi:10.1073/pnas.1000645107
102. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med (1988) 318(20):1315-21. doi:10.1056/NEJM198805193182007
103. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 105(7):816-22. doi:10.1161/hc0702.104183
104. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A (2000) 97(17):9735-40. doi:10.1073/pnas.97.17.9735
105. Dumas A, Dierksen GA, Gurol ME, Halpin A, Martinez-Ramirez S, Schwab K, et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol (2012) 72(1):76-81. doi:10.1002/ana.23566
106. den Abeelen AS, Lagro J, van Beek AH, Claassen JA. Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's disease. Curr Alzheimer Res (2014) 11(1):11-7. doi:10.2174/1567205010666131119234845
107. Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, et al. Obesity and diabetes cause cognitive dysfunction in the absence of accelerated beta-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun (2014) 2(1):64. doi:10.1186/2051-5960-2-64
108. Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, et al. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiol Aging (2014) 35(3):576-84. doi:10.1016/j.neurobiolaging.2013.09.028
109. Macdonald IR, DeBay DR, Reid GA, O'Leary TP, Jollymore CT, Mawko G, et al. Early detection of cerebral glucose uptake changes in the 5XFAD mouse. Curr Alzheimer Res (2014) 11(5):450-60. doi:10.2174/1567205011666140505111354
110. Do TM, Alata W, Dodacki A, Traversy MT, Chacun H, Pradier L, et al. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease. Neuropharmacology (2014) 81:311-7. doi:10.1016/j.neuropharm.2014.02.010
111. Pedrós I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas-Zarate C, et al. Early alterations in energy metabolism in the hippocampus of APPSwe/PS1dE9 mouse model of Alzheimer's disease. Biochim Biophys Acta (2014) 1842(9):1556-66. doi:10.1016/j.bbadis.2014.05.025
112. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through tau phosphorylation. Neuron (2013) 78(1):94-108. doi:10.1016/j.neuron.2013.02.003
113. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 8(3):247-68.
114. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 122(4):1316-38. doi:10.1172/JCI59903
115. Hokama M, Oka S, Leon J, Ninomiya T, Honda H, Sasaki K, et al. Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex (2013) 24(9):2476-88. doi:10.1093/cercor/bht101
116. Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, et al. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys. Cell Metab (2013) 18(6):831-43. doi:10.1016/j.cmet.2013.11.002
117. Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, et al. Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci (2011) 4(2):118-27. doi:10.2174/1874609811104020118
118. Takeda S, Sato N, Rakugi H, Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst (2011) 7(6):1822-7. doi:10.1039/c0mb00302f
119. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 118(1):53-69. doi:10.1007/s00401-009-0486-3
120. Iqbal K, Alonso AC, Gong CX, Khatoon S, Singh TJ, Grundke-Iqbal I. Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol Neurobiol (1994) 9(1-3):119-23. doi:10.1007/BF02816111
121. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology (2009) 150(12):5294-301. doi:10.1210/en.2009-0695
122. Qu Z, Jiao Z, Sun X, Zhao Y, Ren J, Xu G. Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. Brain Res (2011) 1383:300-6. doi:10.1016/j.brainres.2011.01.084
123. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 86(15):3265-74. doi:10.1002/jnr.21787
124. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes (2006) 55(12):3320-5. doi:10.2337/db06-0485
125. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 4(11):e7917. doi:10.1371/journal.pone.0007917
126. Takalo M, Haapasalo A, Martiskainen H, Kurkinen KM, Koivisto H, Miettinen P, et al. High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. J Nutr Biochem (2014) 25(6):634-41. doi:10.1016/j.jnutbio.2014.02.003
127. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem (2009) 111(1):242-9. doi:10.1111/j.1471-4159.2009.06320.x
128. El Khoury NB, Gratuze M, Papon MA, Bretteville A, Planel E. Insulin dysfunction and tau pathology. Front Cell Neurosci (2014) 8:22. doi:10.3389/fncel.2014.00022
129. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem (1997) 272(31):19547-53. doi:10.1074/jbc.272.31.19547
130. Schechter R, Beju D, Miller KE. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun (2005) 334(4):979-86. doi:10.1016/j.bbrc.2005.07.001
131. Freude S, Hettich MM, Schumann C, Stöhr O, Koch L, Köhler C, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J (2009) 23(10):3315-24. doi:10.1096/fj.09-132043
132. Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 386(1):257-62. doi:10.1016/j.bbrc.2009.06.032
133. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci (2003) 23(18):7084-92.
134. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A. Neuron (1996) 17(6):1201-7. doi:10.1016/S0896-6273(00)80250-0
135. Abbondante S, Baglietto-Vargas D, Rodriguez-Ortiz CJ, Estrada-Hernandez T, Medeiros R, Laferla FM. Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes. Am J Pathol (2014) 184(3):819-26. doi:10.1016/j.ajpath.2013.11.021
136. Ravona-Springer R, Heymann A, Schmeidler J, Sano M, Preiss R, Koifman K, et al. The ApoE4 genotype modifies the relationship of long-term glycemic control with cognitive functioning in elderly with type 2 diabetes. Eur Neuropsychopharmacol (2014) 24(8):1303-8. doi:10.1016/j.euroneuro.2014.05.001